Diagnostic Uses of Common Eye Drops.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2024-07-01 Epub Date: 2024-04-03 DOI:10.1089/jop.2024.0017

Eugene Michael, Vidit Singh

引用次数: 0

Abstract

Medicated eye drops may have dual therapeutic and diagnostic uses that form part of the ophthalmic assessment paradigm. In this review article, commonly administered and prescribed eye drops were analyzed for their use as a diagnostic tool. It examines the common categories of eye drops-antimicrobial agents, topical anesthetics, mydriatics, and ocular anti-hypertensives, with respect to their therapeutic and diagnostic applications. Knowledge of the pharmacological effects of eye drops is an important aspect in performing clinical duties. Diagnostic tests by utilization of eye drops are safe, efficient, noninvasive, and informative to the eye care professional.

查看原文本刊更多论文

普通眼药水的诊断用途。

滴眼液可能具有双重治疗和诊断用途，是眼科评估范例的一部分。在这篇综述文章中，分析了常用和处方眼药水作为诊断工具的用途。文章研究了眼药水的常见类别--抗菌剂、局部麻醉剂、眼药水和眼部降压药--在治疗和诊断方面的应用。了解眼药水的药理作用是履行临床职责的一个重要方面。利用滴眼液进行诊断测试安全、高效、无创，而且能为眼科护理专业人员提供信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Ocular Pharmacology and Therapeutics 医学-眼科学

CiteScore

4.60

自引率

4.30%

发文量

审稿时长

1 months

期刊介绍： Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics coverage includes: Glaucoma Cataracts Retinal degeneration Ocular infection, trauma, and toxicology Ocular drug delivery and biotransformation Ocular pharmacotherapy/clinical trials Ocular inflammatory and immune disorders Gene and cell-based therapies Ocular metabolic disorders Ocular ischemia and blood flow Proliferative disorders of the eye Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.